MASI
Masimo Corporation
NASDAQ · Healthcare · Medical - Instruments & Supplies · US
$179.95
+0.00%Income statement
| Metric | TTM | 2026 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1.6B | 1.5B | 2.1B | 2.0B | 2.0B |
| Cost of Revenue | 596.5M | 581.7M | 1.1B | 1.0B | 977.0M |
| Gross Profit | 962.0M | 945.2M | 1.0B | 1.0B | 1.1B |
| Operating Expenses | |||||
| R&D Expense | 122.5M | 126.4M | 222.8M | 175.2M | 191.4M |
| SG&A Expense | 530.0M | 506.0M | 743.8M | 664.0M | 657.4M |
| General & Admin Expense | — | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 100.0K | — | 304.5M | 27.8M | — |
| Total Operating Expenses | 652.6M | 632.4M | 1.3B | 867.0M | 848.8M |
| Cost and Expenses | 1.2B | 1.2B | 2.4B | 1.9B | 1.8B |
| Operating Income (EBIT) | 309.4M | 312.8M | (266.7M) | 136.5M | 210.0M |
| Non-Operating | |||||
| Interest Income | 3.0M | 3.4M | 4.8M | 3.0M | 1.8M |
| Interest Expense | 30.6M | 33.2M | 43.6M | 50.3M | 25.7M |
| Net Interest Income | (27.6M) | (29.8M) | (38.8M) | (47.3M) | (23.9M) |
| Other Non-Op Income/Expense | (33.8M) | (40.2M) | (38.6M) | (48.4M) | (16.6M) |
| Non-Operating Income (excl Interest) | 3.2M | 7.0M | (5.0M) | (1.9M) | (9.1M) |
| EBT (Pre-Tax Income) | 275.6M | 272.6M | (305.3M) | 88.1M | 193.4M |
| Income Tax Expense | 58.8M | 64.9M | (400.0K) | 6.6M | 49.9M |
| Bottom Line | |||||
| Net Income | 76.3M | (151.5M) | (304.9M) | 81.5M | 143.5M |
| Earnings from Cont. Ops | 216.8M | 207.7M | (304.9M) | 81.5M | 143.5M |
| Earnings from Discont. Ops | (140.5M) | (359.2M) | — | — | — |
| Bottom Line Net Income | 76.3M | (151.5M) | (304.9M) | 81.5M | 143.5M |
| Per Share | |||||
| Basic EPS | $1.44 | ($2.83) | ($5.72) | $1.54 | $2.68 |
| Diluted EPS | $1.46 | ($2.80) | ($5.72) | $1.51 | $2.60 |
| Revenue Per Share | $29.86 | $28.49 | $39.29 | $38.79 | $37.98 |
| Shares | |||||
| Basic Shares Outstanding | 52.2M | 53.6M | 53.3M | 52.8M | 53.6M |
| Diluted Shares Outstanding | 52.6M | 54.2M | 53.3M | 54.1M | 55.2M |
| Profitability Metrics | |||||
| EBITDA | 344.5M | 344.6M | (158.7M) | 236.7M | 355.2M |
| D&A | 38.3M | 38.8M | 103.0M | 98.3M | 136.1M |
| EBIT | 306.2M | 305.8M | (261.7M) | 138.4M | 219.1M |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Apr 1, 2026